GeoVax Labs Stock Price, News & Analysis (NASDAQ:GOVXW) $0.10 +0.02 (+25.35%) (As of 12/1/2023 ET) Add Compare Share Share Today's Range$0.09▼$0.1050-Day Range$0.04▼$0.1552-Week Range$0.04▼$0.35Volume300 shsAverage Volume3,870 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsFinancialsHeadlinesSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsFinancialsHeadlinesSEC FilingsShort InterestSocial Media About GeoVax Labs Stock (NASDAQ:GOVXW)geovax labs, inc., (otcqb: govx) is a clinical-stage biotechnology company developing human vaccines against infectious diseases using our modified vaccinia ankara - virus-like particle (mva-vlp) vaccine platform. our development programs are focused on preventive vaccines against hiv, zika virus, hemorrhagic fever viruses (ebola, sudan, marburg, and lassa), and malaria, as well as therapeutic vaccines for chronic hepatitis b infections and cancers. our mva-vlp platform supports in vivo production of non-infectious vlps from the cells of the very person receiving the vaccine, mimicking a natural infection, and stimulating both the humoral and cellular arms of the immune system to recognize, prevent, and control the target infection. for more information, visit www.geovax.com.Read More GOVXW Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GOVXW Stock News HeadlinesNovember 14, 2023 | finance.yahoo.comProgress on GeoVax’s Universal Coronavirus Vaccine Candidate, GEO-CM02, Presented at Vaccines Summit 2023November 8, 2023 | finance.yahoo.comGeoVax Reports Third Quarter 2023 Financial Results and Provides Business UpdateDecember 2, 2023 | DTI Trader (Ad)New CBOE “special perk” helps traders target income every weekendYou might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. October 30, 2023 | finance.yahoo.comGeoVax Commences Site Expansion for Phase 2 Trial of Next-Generation COVID-19 VaccineOctober 25, 2023 | finance.yahoo.comGeoVax to Participate in Upcoming November Investor and Industry EventsOctober 9, 2023 | finance.yahoo.comGeoVax Receives Notice of Allowance for Marburg Vaccine PatentOctober 5, 2023 | finance.yahoo.comGeoVax Receives Notice of Allowance for HIV Vaccine PatentSeptember 26, 2023 | finance.yahoo.comGeoVax Secures Multi-Product License for ProBioGen's AGE1.CR.pIX® Suspension Cell Line to Bolster MVA-Based Vaccine DevelopmentDecember 2, 2023 | DTI Trader (Ad)New CBOE “special perk” helps traders target income every weekendYou might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. September 20, 2023 | finance.yahoo.comGeoVax Next-Generation COVID-19 Vaccine Data Presented at Keystone Symposia ConferenceAugust 29, 2023 | finance.yahoo.comGeoVax to Present at the Emerging Growth Conference on September 6, 2023August 10, 2023 | finance.yahoo.comGeoVax Announces First Patients Vaccinated in Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic LeukemiaAugust 9, 2023 | finance.yahoo.comGeoVax Reports 2023 Second Quarter Financial Results and Provides Corporate UpdateJuly 24, 2023 | marketwatch.comGeoVax Labs Shares Rise 8% After Patent for Ebola VaccineJuly 11, 2023 | finance.yahoo.comGOVX - GeoVax Labs, Inc.July 10, 2023 | finance.yahoo.comGeoVax Presents Gedeptin® Clinical Data at the AACR-AHNS Head and Neck Cancer ConferenceMay 24, 2023 | finance.yahoo.comGeoVax’s Next-Generation COVID-19 Vaccine Shows High Immunogenicity in Immunocompromised PatientsMay 9, 2023 | finance.yahoo.comGeoVax Labs to Participate in A.G.P.’s Virtual Healthcare ConferenceMay 8, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: GeoVax Labs (GOVX), Selecta Biosciences (SELB) and Assembly Biosciences (ASMB)April 26, 2023 | finance.yahoo.comGeoVax to Participate in the 4th Symposium on Infectious Diseases in the Immunocompromised HostApril 25, 2023 | finance.yahoo.comGeoVax to Host First Quarter 2023 Business Update and Financial Results Conference Call on May 4, 2023April 6, 2023 | finanznachrichten.deGeoVax, Inc.: GeoVax Announces Presentation of Preliminary Data from Clinical Trial of Next-Generation COVID-19 Vaccine CandidateMarch 27, 2023 | finance.yahoo.comGeoVax Labs, Inc. (NASDAQ:GOVX) Q4 2022 Earnings Call TranscriptMarch 24, 2023 | finanznachrichten.deGeoVax, Inc.: GeoVax Reports 2022 Year-End Financial Results and Provides Corporate UpdateFebruary 8, 2023 | finance.yahoo.comGeoVax Announces Decisive Progress in Establishing High-Capacity, Continuous Cell Line System to Manufacture MVA-based VaccinesNovember 9, 2022 | finance.yahoo.comGeoVax Reports 2022 Third Quarter Financial Results and Provides Corporate UpdateOctober 26, 2022 | finance.yahoo.comGeoVax to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 9, 2022See More Headlines Receive GOVXW Stock News and Ratings via Email Sign-up to receive the latest news and ratings for GeoVax Labs and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Research & Development In Biotechnology Sub-IndustryN/A SectorBusiness Services Current SymbolNASDAQ:GOVXW CUSIPN/A CIK832489 Webwww.geovax.com Phone16783847220FaxN/AEmployees26Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$81,526.00 Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key CompetitorsCyclo TherapeuticsNASDAQ:CYTHWBuzzFeedNASDAQ:BZFDWCaravelle International GroupNASDAQ:CACOCreative Realities, Inc. WT EXP 110922NASDAQ:CREXWDirect DigitalNASDAQ:DRCTWView All Competitors GOVXW Stock Analysis - Frequently Asked Questions How have GOVXW shares performed in 2023? GeoVax Labs' stock was trading at $0.15 at the beginning of 2023. Since then, GOVXW shares have decreased by 34.1% and is now trading at $0.0989. View the best growth stocks for 2023 here. Are investors shorting GeoVax Labs? GeoVax Labs saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 1,300 shares, an increase of 44.4% from the October 31st total of 900 shares. Based on an average daily trading volume, of 2,000 shares, the short-interest ratio is currently 0.7 days. View GeoVax Labs' Short Interest. How do I buy shares of GeoVax Labs? Shares of GOVXW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:GOVXW) was last updated on 12/2/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GeoVax Labs, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.